Table 1 Comparison of clinical data between thyroid dysfunction group and normal thyroid function group
Thyroid dysfunction group (n = 113) | Normal thyroid function group (n = 82) | P | t/ x2/Z | |
|---|---|---|---|---|
Gender (n, %) | 0.131 | 2.280 | ||
Male | 85(75.2) | 69(84.1) | ||
Female | 28(24.8) | 13(15.9) | ||
Age(years,x ± s) | 58.6 ± 10.7 | 57.3 ± 9.6 | 0.380 | 0.880 |
BMI | 23.5 ± 3.3 | 22.8 ± 4.1 | 0.235 | 1.193 |
Diabetes | 0.877 | 0.024 | ||
Yes | 17(15.0) | 13(15.9) | ||
No | 96(85.0) | 69(84.1) | ||
Evaluation time [weeks,M(Q1,Q3)] | 10.0(3.0, 25.5) | 10.0(5.7, 21.0) | 0.503 | 0.669 |
Hepatocellular carcinoma (n,%) | 0.786 | 0.074 | ||
Yes | 105(92.9) | 77(93.9) | ||
No | 8(7.1) | 5(6.1) | ||
Staging of BCLC system(n,%) | 0.815 | 0.054 | ||
B | 25(22.1) | 17(20.7) | ||
C | 88(77.9) | 65(79.3) | ||
HBV or HCV(n,%) | 101(85.8) | 69(79.3) | 0.280 | 1.165 |
Cirrhosis (n,%) | 92(80.5) | 68(87.8) | 0.786 | 0.074 |
Decompensation stage (n,%) | 0.371 | 0.799 | ||
Yes | 50(44.2) | 39(47.6) | ||
No | 42(55.8) | 43(52.4) | ||
Previous or combined treatment (n,%) | ||||
Surgical resection | 16(14.2) | 16(19.5) | 0.319 | 0.993 |
TAE or TACE | 85(75.2) | 52(63.4) | 0.094 | 2.810 |
Tumor ablation | 55(48.7) | 42(51.2) | 0.725 | 0.123 |
Targeted agent | 77(68.1) | 55(67.1) | 0.875 | 0.025 |
Systemic chemotherapy | 6(5.3) | 4(4.9) | 1.000 | 0.000 |
Radiotherapy | 14(12.4) | 5(6.1) | 0.144 | 2.139 |
Name of PD-1 monoclonal antibody (n,%) | 0.591 | 0.289 | ||
Sintilimab | 59(52.2) | 46(56.1) | ||
Camrelizumab | 54(47.8) | 36(43.9) | ||
Thyroid antibody (n,%) | 0.041 | – | ||
Positive | 7(20.6) | 0(0.0) | ||
Negative | 27(79.4) | 19(100.0) | ||
Thyroid function before treatment of PD-1 | ||||
TSH[mU/L,M(Q1,Q3)] | 2.23(1.42, 3.88) | 2.05(1.33, 3.45) | 0.620 | 0.495 |
FT4[pmol/L,M(Q1,Q3)] | 13.25(11.84, 15.00) | 12.59(11.37, 14.83) | 0.223 | 1.219 |
FT3[pmol/L,M(Q1,Q3)] | 3.86(3.18, 4.42) | 3.80(3.27, 4.32) | 0.962 | 0.047 |
Thyroid function after treatment of PD-1 | ||||
TSH[mU/L,M(Q1,Q3)] | 6.20(1.42, 10.17) | 2.16(1.52, 3.22) | 0.000 | 5.198 |
FT4[pmol/L,M(Q1,Q3)] | 12.18(10.54, 14.33) | 12.32(11.60, 13.89) | 0.398 | 0.845 |
FT3[pmol/L,M(Q1,Q3)] | 3.68(2.93, 4.40) | 3.80(2.96, 4.28) | 0.675 | 0.420 |